Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results